Cargando…

Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials

BACKGROUND: Zoledronic acid (ZA) does not improve the overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC); however, little is known about the efficacy of ZA in to hormone-sensitive prostate cancer (HSPC), metastatic hormone-sensitive prostate cancer (mHSPC), and non- met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chiwei, Lin, Mandi, Yu, Daocheng, Qin, Weiting, Zhou, Jianfu, Guo, Lang, Huang, Renlun, Fan, Xinxiang, Xiang, Songtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499269/ https://www.ncbi.nlm.nih.gov/pubmed/36137135 http://dx.doi.org/10.1371/journal.pone.0275176

Ejemplares similares

Formation of pre-metastatic bone niche in prostate cancer and regulation of traditional chinese medicine
por: Chen, Chiwei, et al.
Publicado: (2022)

System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma
por: Huang, Renlun, et al.
Publicado: (2023)

Research Trends and Regulation of CCL5 in Prostate Cancer
por: Huang, Renlun, et al.
Publicado: (2021)

CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling
por: Huang, Renlun, et al.
Publicado: (2020)

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis
por: Gálvez, Rafael, et al.
Publicado: (2008)

Functionalized Selenium Nanotherapeutics Synergizes With Zoledronic Acid to Suppress Prostate Cancer Cell Growth Through Induction of Mitochondria-Mediated Apoptosis and Cell Cycle S Phase Arrest
por: An, Yulin, et al.
Publicado: (2021)

566 Burn Disparities: Do Race, Gender and Insurance Status Affect Mortality?
por: Satahoo, Shevonne, et al.
Publicado: (2022)

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm
por: Zhou, Jianfu, et al.
Publicado: (2020)

Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
por: Kojima, Ippei, et al.
Publicado: (2019)

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
por: Wang, Sheng, et al.
Publicado: (2023)

Acupressure versus parecoxib sodium in acute renal colic: A prospective cohort study
por: Chen, Chiwei, et al.
Publicado: (2023)

Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
por: Zhou, Jianfu, et al.
Publicado: (2021)

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
por: Serefoglu, Ege Can, et al.
Publicado: (2010)

Identifying therapeutic biomarkers of zoledronic acid by metabolomics
por: Li, Xiang, et al.
Publicado: (2023)

Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis
por: Al-Agha, Abdulmoein E., et al.
Publicado: (2016)

Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Do congenital prosopagnosia and the other-race effect affect the same face recognition mechanisms?
por: Esins, Janina, et al.
Publicado: (2014)

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
por: Brubaker, Kristen D, et al.
Publicado: (2006)

Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells
por: Goffinet, M, et al.
Publicado: (2006)

Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms
por: Li, Chong, et al.
Publicado: (2022)

Retrospective assessment of tolerability and efficacy of zoledronate in the palliative treatment of cancer‐bearing dogs
por: Lopes, MG, et al.
Publicado: (2022)

Corrigendum: Do congenital prosopagnosia and the other-race effect affect the same face recognition mechanisms?
por: Esins, Janina, et al.
Publicado: (2015)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
por: Richhariya, Akshara, et al.
Publicado: (2012)

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2019)

Race and Socioeconomic Status Independently Affect Risk of Major Amputation in Peripheral Artery Disease
por: Arya, Shipra, et al.
Publicado: (2018)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Long-Term Efficacy of Intensive Zoledronate Therapy and Predictors of Retreatment in Paget’s Disease of Bone
por: Barale, Marco, et al.
Publicado: (2021)

The effect of zoledronate during bone healing
por: Matos, Marcos Almeida, et al.
Publicado: (2010)

The anti-tumour effects of zoledronic acid
por: Zekri, Jamal, et al.
Publicado: (2014)

Zoledronic Acid–Induced Interface Dermatitis
por: Succaria, Farah, et al.
Publicado: (2015)

Race, caste, and status : Indians in colonial Spanish America /
por: Jackson, Robert H. (Robert Howard)
Publicado: (1999)

Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers
por: Almubarak, Hussain, et al.
Publicado: (2011)

A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer
por: Hong, Sung Joon, et al.
Publicado: (2007)

Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2020)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0o3ena5qbvak2qug26csl323d7